T3	condition 35 49	cardiotoxicity
T4	eligibility 53 99	women with breast cancer receiving trastuzumab
T5	outcome-Measure 1101 1142	comparison of incidence of cardiotoxicity
T6	outcome-Measure 1151 1169	comparison of LVEF
T7	total-participants 1430 1433	468
T1	intervention 0 22	Lisinopril or Coreg CR
T8	eligibility 983 1064	patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy
